Oculis secures CHF 100 million loan facility to accelerate eye care innovation

Oculis is making bold financial moves to support its mission of transforming eye care. A newly expanded loan facility boosts its ability to advance breakthrough treatments.

Oculis Holding AG has announced an upsized loan facility, granting the company access to up to CHF 100 million in flexible financing. This move strengthens its financial position as it advances a pipeline of ophthalmic treatments targeting both front and back-of-the-eye diseases. The revised facility builds on a previously established CHF 50 million agreement from May 2024, now doubled in size to reflect growing investor confidence and strategic momentum.

The facility, provided by funds managed by BlackRock, is structured in three tranches of CHF 25 million each, with an additional optional tranche of up to CHF 25 million. This flexible approach enables Oculis to access capital in stages as needed, minimizing dilution while supporting critical R&D programs and potential commercialization activities. It complements the company’s recent USD 100 million equity raise, further reinforcing its capacity to execute on late-stage clinical trials and regulatory initiatives.

This financing milestone arrives at a pivotal time for Oculis as it seeks to bring breakthrough therapies to market. With a strong financial foundation and backing from top-tier institutional investors, the company is well-positioned to deliver on its mission of transforming treatment for patients with serious eye conditions worldwide.

“We are pleased to have upsized our previous loan agreement with funds and accounts managed by BlackRock, which expands an instrument allowing enhanced flexibility to ensure the future financial and operational strength of Oculis. Our current robust cash position provides runway into early 2028, which is further strengthened by the loan facility, as we remain focused on advancing our portfolio of differentiated assets and bringing transformative treatments to those who need them most,” said Riad Sherif, M.D., CEO of Oculis.

Oculis was ranked at the TOP 100 Swiss Startup Award in 2020 and 2022.


Riad Sherif (CEO), Gudrun Bachmann (CTO), and Sylvia Cheung (CFO)